You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Novel QcrB Inhibitors for the Treatment of Tuberculosis

    SBC: LGENIA INC.            Topic: NIAID

    Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Novel OCT Technology for Detection of Occult Sperm in the Testes inNon- Obstructed Azoospermia.

    SBC: UNASPER, INC.            Topic: NICHD

    Non-obstructive azoospermia (NOA), a lack of sperm in the ejaculate due to defective spermatogenesis, affects as many as 100,000 men in the US, and represents an unmet medical need because many of these men would like to father children, but cannot without surgical intervention. Current therapy for such men is suboptimal, because it relies upon microsurgical testicular sperm extraction (micro-TESE ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORPORATION            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable an ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  4. Novel Activin A Antagonists for Treatment of Osteoporosis

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder

    SBC: Biomedical Development Corporation            Topic: 103

    DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Nanoliter electron paramagnetic resonance sensor based on diamond nanophotonics: a new tool for biomarker monitoring

    SBC: ODMR Technologies, Inc            Topic: 400

    DESCRIPTION provided by applicant ODMR Technologies Inc together with Victor Acostaandapos s group at University of New Mexico is developing a nanophotonic platform capable of uniquely detecting minute quantities of biomolecules The specific detection of biomolecules plays a central role in modern life science including cell systems biology high throughput drug scre ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance

    SBC: EXSCIEN CORPORATION            Topic: NIDDK

    DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. MITOCHONDRIAL RESPIROMETRY IN FROZEN BIOLOGICAL SAMPLES

    SBC: Enspire Bio, Inc.            Topic: NIEHS

    AbstractImpaired mitochondrial respiration plays a key role in metabolic, cardiovascular, and aging-related diseases. However, mitochondrial respirometry analysis currently requires processing of the living tissue sample within an hour after being taken from the patient. This requirement makes respirometry analysis largely unfeasible to standard clinical practice and clinical studies. We invented ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Mechanistic Studies of a Novel Small Molecule HIV Inhibitor

    SBC: ADVANCED GENETIC SYSTEMS, INC.            Topic: 100

    DESCRIPTION provided by applicant There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens The Rev RRE protein RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged Previously we identified the thienopyridine scaffold that inhibited HIV ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government